- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02673879
IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion (IMPI-2)
A Trial of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults With Large Pericardial Effusion Due to Tuberculous and Non-tuberculous Pericarditis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Intrapericardial fibrinolytic agents are used in the drainage of tuberculous, purulent, neoplastic and other inflammatory pericardial effusions to prevent recurrent effusions and constrictive pericarditis. This use is based on evidence from case reports and a small trial that did not have the statistical power to reliably evaluate the effect of pericardial drainage facilitated by intrapericardial fibrinolysis on safety and important clinical outcomes.
The Second Investigation of the Management of Pericarditis (IMPI-2) Trial will compare the effectiveness and safety of complete percutaneous pericardial drainage facilitated by intrapericardial alteplase (recombinant human tissue-type plasminogen activator) to conventional pericardiocentesis when indicated in 2176 patients with large pericardial effusion due to tuberculous and non-tuberculous pericarditis. An internal pilot study of 218 patients will initially confirm the feasibility of conducting a large-scale multi-centre clinical trial of intrapericardial fibrinolysis in patients with large pericardial effusion, and also provide preliminary safety data, following a dose finding study of intrapericardial alteplase.
Hypothesis: We hypothesise that patients with large pericardial effusion randomized to intrapericardial alteplase to ensure complete pericardial drainage will have at least a 35% reduction in cardiac tamponade requiring pericardiocentesis or constrictive pericarditis compared to conventional pericardiocentesis when indicated.
Objectives: The primary objectives of the IMPI-2 Trial are:
- To demonstrate the feasibility of conducting a multicentre clinical trial of intrapericardial fibrinolysis in patients with large pericardial effusion, and to assess the safety of intrapericardial alteplase in an internal pilot study, and
- To determine the effectiveness of intrapericardial alteplase in reducing the composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis in patients with large pericardial effusion in the full trial.
Should the internal pilot study demonstrate feasibility and safety; all 218 patients will be rolled-over into the full scale IMPI-2 trial of 2176 participants. The primary outcome is the first occurrence of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis. The secondary safety endpoint is safety of intrapericardial fibrinolysis measured by effect on major bleeding, and serious and non-serious adverse events. The secondary efficacy outcomes are constrictive pericarditis, and cardiac tamponade requiring pericardiocentesis, analysed separately, and persistent or recurrent pericardial effusion without cardiac tamponade, hospitalisation, and death. The secondary diagnostic outcomes are proportion with bacteriologically confirmed tuberculosis from any organ or tissue; time to diagnosis of bacteriologically confirmed tuberculosis in days; accuracy of novel tests for the diagnosis of tuberculosis; proportion with specific diagnosis of any pericardial disease; time to diagnosis of a specific pericardial disease in days.
Study Design: IMPI-2 is a prospective randomized open blinded end-point trial that will enroll 2176 patients with large pericardial effusion over 36 months from up to 30 centres in South Africa and Africa. Eligible patients will be randomly assigned to receive complete pericardial drainage facilitated by intrapericardial fibrinolysis or conventional pericardiocentesis when indicated on enrollment to the study. Patients will be followed at 2 weeks, 6 weeks, 12 weeks, and in months 6, and 12 after enrollment. The IMPI Project Office, University of Cape Town, South Africa will manage and coordinate the study in association with the Pericarditis Research Unit, Walter Sisulu University, South Africa and the Population Health Research Institute, McMaster University, Canada.
Importance: IMPI-2 addresses very serious complications of large pericardial effusion (i.e., cardiac tamponade and constrictive pericarditis), which are associated with high mortality despite pericardiocentesis or pericardiectomy. This study will utilise the research network that was established by the IMPI trial which was completed in 2014.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Veronica Francis
- Phone Number: +27832449895
- Email: veronica.francis@uct.ac.za
Study Contact Backup
- Name: Abolade A Awotedu, MBBS
- Phone Number: +27822007694
- Email: bolaawotedu@gmail.com
Study Locations
-
-
Western Cape
-
Cape Town, Western Cape, South Africa, 7925
- Recruiting
- Groote Schuur Hospital
-
Contact:
- Veronica Francis
- Phone Number: +27832449895
- Email: veronica.francis@uct.ac.za
-
Contact:
- Shaheen Pandie, MMed (Med)
- Phone Number: +27823199030
- Email: s.pandie@uct.ac.za
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years of age;
- Confirmed large pericardial effusion on echocardiography (i.e., echo free space ≥1 cm anterior to the right ventricle of the heart in diastole);
- Willingness to participate for the full duration of the trial (i.e., 12 months); and
- Provision of written informed consent.
Exclusion Criteria:
- Age < 18 years;
- Uraemic pericarditis (i.e., urea > 21.4 mmol/l);
- Thrombocytopenia (i.e., < 100,000 platelets per µl);
- Presence of a contra-indication to the administration of a fibrinolytic agent (i.e., major haemorrhage or major trauma; coincidental stroke; major surgery in the previous 5 days; blood pressure >200/100 mmHg).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pericardiocentesis with Alteplase
Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase.
|
Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
|
Other: Conventional Pericardiocentesis
Conventional pericardiocentesis when indicated.
|
Conventional pericardiocentesis when indicated
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite outcome of cardiac tamponade requiring pericardiocentesis or constrictive pericarditis.
Time Frame: 12 months
|
Cardiac tamponade requiring pericardiocentesis shall refer to a combination of physical and echocardiographic findings, i.e., patients with clinical signs of tachycardia (> 90 bpm), hypotension (systolic blood pressure < 100 mmHg), elevated jugular venous pressure and/or pulsus paradoxus > 10 mmHg plus evidence of a large pericardial effusion with echocardiographic signs of tamponade in the absence of other cardiac disease, as defined in the IMPI trial. Constrictive pericarditis shall refer to a combination of physical and echocardiographic findings (i.e., patients with a prior history of pericardial effusion who have pulsus paradoxus, a raised jugular venous pressure with or without evidence of pericardial thickening on imaging) in the absence of either large pericardial effusion or other cardiac disease, as described in the IMPI trial. |
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major bleeding
Time Frame: 12 months
|
Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in the haemoglobin level of 2 g per decilitre or more over a 24-hour period, transfusion of 2 or more units of packed red cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding
|
12 months
|
Clinically relevant non-major bleeding
Time Frame: 12 months
|
Defined as clinically overt bleeding that does not satisfy the criteria for major bleeding and that leads to hospital admission, physician-guided medical or surgical treatment.
|
12 months
|
Any bleeding
Time Frame: 12 months
|
Any other form of bleeding that is not covered by safety outcomes 1-3
|
12 months
|
Other adverse events
Time Frame: 12 months
|
Any other adverse events
|
12 months
|
Persistent pericardial effusion without cardiac tamponade
Time Frame: 12 months
|
Refers to the echocardiographic presence of a pericardial effusion without criteria for cardiac tamponade requiring pericarditis during follow-up visits.
The pericardial effusion is the same size or larger than that measured at the time of enrollment (where no pericardiocentesis was done) or post-pericardiocentesis.
|
12 months
|
Recurrent pericardial effusion without cardiac tamponade
Time Frame: 12 months
|
Refers to the echocardiographic presence of a pericardial effusion without criteria for cardiac tamponade requiring pericarditis during follow-up visits.
Recurrence is present in the context of re-appearance of a pericardial effusion in the context where complete drainage was performed.
|
12 months
|
Hospitalisation for any cause; and death from any cause
Time Frame: 12 months
|
Refers to admission to hospital for at least 24 hours for any reason.
|
12 months
|
Cardiac tamponade requiring pericardiocentesis
Time Frame: 12 months
|
Cardiac tamponade requiring pericardiocentesis shall refer to a combination of physical and echocardiographic findings, i.e., patients with clinical signs of tachycardia (> 90 bpm), hypotension (systolic blood pressure < 100 mmHg), elevated jugular venous pressure and/or pulsus paradoxus > 10 mmHg plus evidence of a large pericardial effusion with echocardiographic signs of tamponade in the absence of other cardiac disease, as defined in the IMPI trial.
|
12 months
|
Constrictive pericarditis
Time Frame: 12 months
|
Constrictive pericarditis shall refer to a combination of physical and echocardiographic findings (i.e., patients with a prior history of pericardial effusion who have pulsus paradoxus, a raised jugular venous pressure with or without evidence of pericardial thickening on imaging) in the absence of either large pericardial effusion or other cardiac disease, as described in the IMPI trial.
|
12 months
|
Death
Time Frame: 12 months
|
Death from any cause
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion with proven tuberculosis
Time Frame: 12 months
|
The proportion with bacteriologically confirmed tuberculosis from any organ or tissue in each group will be based on findings on microscopy, Xpert MRB/RIF, culture, and / histology .
|
12 months
|
Time to diagnosis of proven tuberculosis
Time Frame: 12 months
|
The time to diagnosis of bacteriologically confirmed tuberculosis in days in each group will be based on the date of sample collection and the date of first bacteriological confirmation from any organ or tissue.
|
12 months
|
Proportion with proven tuberculosis on novel tests who are not put on treatment
Time Frame: 12 months
|
The proportion of culture-positive tuberculosis cases who are not placed on treatment in either arm, or the proportion of these which would have been detected by the novel rapid index tests.
|
12 months
|
Diagnostic accuracy of novel tests of tuberculosis
Time Frame: 12 months
|
The diagnostic accuracy of novel tests (e.g., Xpert MTB/RIF, Xpert ULTRA, InterGam) for the detection of culture-positive pericardial tuberculosis (a secondary analysis will be performed using clinically-diagnosed tuberculosis as reference standard)
|
12 months
|
Drug resistant tuberculosis
Time Frame: 12 months
|
The proportion of drug-resistant tuberculosis cases detected.
|
12 months
|
Specific diagnosis of tuberculous pericarditis
Time Frame: 12 months
|
The proportion with a specific diagnosis of pericardial disease in each group will be based on findings on results of investigations for tuberculosis, cancer, purulent pericarditis and other disease.
|
12 months
|
Time to diagnosis of specific pericardial disease
Time Frame: 12 months
|
The time to diagnosis of a specific pericardial disease in days in each group will be based on the date of sample collection and the date of first definitive result.
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bongani M Mayosi, DPhil, University of Cape Town
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HREC REF No. 370/2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pericardial Effusion
-
Japan Clinical Oncology GroupMinistry of Health, Labour and Welfare, JapanCompletedMalignant Pericardial EffusionJapan
-
Chinese University of Hong KongRecruitingPericardial Effusion MalignantHong Kong
-
French Cardiology SocietyFrench Federation of CardiologyCompleted
-
French Cardiology SocietyClinact; CLIPACompletedPericardial EffusionFrance
-
ASST Fatebenefratelli SaccoNot yet recruitingPericardial Disease | Autoinflammatory Disease | Acute Pericarditis | Pericardial Effusion | Pericardial Fluid Exudate | Autoinflammatory Disorders
-
Sohag UniversityCompleted
-
Assiut UniversityUnknownAscites | Pericardial Effusion | Effusion PleuralEgypt
-
Maria Vittoria HospitalUnknown
-
Montreal Heart InstituteJohnson & JohnsonCompletedPericardial Effusion | Late Cardiac Tamponade | Surgical ReinterventionCanada
-
Aarhus University Hospital SkejbyCompletedHeart Disease | Pleural Effusion | Pericardial EffusionDenmark
Clinical Trials on Pericardiocentesis with Alteplase
-
National Heart, Lung, and Blood Institute (NHLBI)Terminated
-
University Hospital, CaenSuspendedSubarachnoid HemorrhageFrance
-
Centre Hospitalier Sud FrancilienCompletedAcute Ischemic Stroke Due to Medium-vessel-occlusionFrance
-
Centre Hospitalier Sud FrancilienCompletedAcute Anterior Choroidal Infarction (ACI) | Paramedian Pontine Infarction (IPP)France
-
ASST Fatebenefratelli SaccoNot yet recruitingPericardial Disease | Autoinflammatory Disease | Acute Pericarditis | Pericardial Effusion | Pericardial Fluid Exudate | Autoinflammatory Disorders
-
University of ManitobaHoffmann-La RocheTerminated
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityShenzhen Hospital of Southern Medical UniversityRecruitingStroke, Acute IschemicChina
-
Niguarda HospitalCompletedStroke | Cerebrovascular AccidentItaly
-
Boehringer IngelheimCompletedAcute Respiratory Distress SyndromeSpain, Germany, Italy, Belgium, Mexico, Netherlands, India, France, Malaysia, Austria, Brazil, Russian Federation, Turkey
-
University of North Carolina, Chapel HillGenentech, Inc.CompletedIschemic StrokeUnited States